Chemomab CM-101 Phase 2a NASH trial meets safety endpoint; shows positive fibrosis biomarker activity

Chemomab Therapeutics Ltd.

Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.
23 NASH patients (F1c-F3) received 8 SC doses of 5 mg/kg or placebo over 16 weeks.
CM-101 showed greater improvements vs placebo in fibrosis biomarkers ProC-3, ProC-4, ProC-18, TIMP-1, ELF.
Nearly 60% of CM-101 patients responded in ≥3 fibrosis biomarkers at week 20 vs 0% placebo.
Higher baseline CCL24 correlated with greater biomarker reductions; FibroScan liver stiffness improved vs placebo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.